Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 8/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248037 | 0.88 | MTNR1B (0.50) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL3249271 | 0.88 | MTNR1B (0.49) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL3246497 | 0.88 | MTNR1B (0.49) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL3246035 | 0.88 | MTNR1B (0.49) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL3252116 | 0.87 | MTNR1B (0.48) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL3249307 | 0.85 | MTNR1B (0.47) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL3245355 | 0.85 | KCNH2 (0.46) | — | |
| SCHEMBL3245357 | 0.85 | KCNH2 (0.46) | — | |
| SCHEMBL3247341 | 0.83 | MTNR1B (0.43) | MTNR1BMTNR1ASRCABL1EGFR | |
| SCHEMBL7726802 | 0.81 | KCNH2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799674-B1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | MTNR1B 2247/4885MTNR1A 2634/4885SRC 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.